Lobular Breast Cancer: Moon Shot Project

Debate between Neil Shastri-Hurst and Seamus Logan

Thursday 9th July 2026 Westminster Hall

[Dr Neil Shastri-Hurst (Solihull West and Shirley) (Con)]

It is a pleasure to serve under your chairmanship today, Mrs Hobhouse. I am grateful to the hon. Member for Horsham (John Milne) for securing today’s debate, and to the Members from across the House who have given their voice to this campaign over a number of years. It is entirely right that Parliament should pause today to consider not just the science, the policy and the funding, but the human reality that sits behind all three of those things.

Behind the words “lobular breast cancer” are people who knew something was wrong, but the system could not prove it. That is the point at the heart of today’s debate. This is not a call for special treatment or a demand that we place one cancer above another; it is a recognition that different cancers behave differently, present differently and may require different approaches if we are serious about improving outcomes.

Today, we are also remembering Dr Susan Michaelis. Many people in public life are described as courageous, but in Susan’s case that word feels insufficient. She was, as we have heard, a commercial pilot, a researcher, a campaigner, a wife and a woman whose instinct, when faced with injustice or uncertainty, was not to turn away from it but to investigate it. She had already devoted much of her professional life to public safety, particularly in the aviation sector. We have heard about how she challenged assumptions, gathered evidence and pursued truth in an area where the consequences mattered for passengers, crews and the wider public. In 2013, she received her devastating diagnosis of invasive lobular breast cancer. As we have heard today, her symptoms were not dramatic; they presented as just a tiny mark on her breast.

Two mammograms and two ultrasounds failed to identify the disease, and it was ultimately identified by an MRI scan. We have heard how that revealed what appeared to be a relatively small lesion of about inch that was later confirmed to be over 7 cm. That single account tells us why this debate continues to matter and shows the particular challenge of a cancer that can be harder to detect through standard imaging.

Remarkably, Susan did not live her final years in retreat from the world; she continued with her work and her research, and continued campaigning. As we have heard, nine days before her death, she travelled to Manchester to help launch the scientific programme for the lobular breast cancer Moon Shot Project, knowing full well that any breakthrough would come too late for her. That is an extraordinary act of generosity and a challenge to all of us in this place. If someone is living with advanced cancer and can spend her final days and the last of her strength ask for progress for others, surely it is our responsibility and Government to find the clarity and urgency to respond.

As we have heard, lobular breast cancer is not rare. It is the second most common type of breast cancer, accounting for around 15% of cases, but despite that it too often remains hidden in plain sight.

[Seamus Logan]

This is not a party-political issue; it is something the shadow Minister and the whole House can agree on. In 2022, the Scottish Government began the process of improving their imaging kits with the introduction of 3D mammography, which is a major step forward. Two months ago, the Scottish Parliament lodged a motion supporting the lobular breast cancer Moon Shot Project and called for the £20 million to be allocated. Does he agree that the breadth of support for this campaign—440 MPs now support it, including myself—is now irresistible, and that the Minister should award the funding?

[Dr Shastri-Hurst]

The hon. Gentleman is right; there is collective support for doing more on this issue. That starts with getting the research right. Without the research, we do not know how to plan for the treatments of the future. I will move on to the other points, but he is also entirely right that this is not a party-political issue, but one that affects all of us and all of our constituents. We have to work with a sense of urgency around it.

As we have heard, the lobular breast cancer Moon Shot Project is looking for £20 million over five years to advance the understanding of invasive lobular breast cancer and to support better detection, treatment and surveillance. We cannot dispute that that is a significant sum, but we have to look at it in the context of national health spending and what cancer costs: the cost to families and patients and the cost to the NHS when it is detected late or treated inadequately. We have to bear those factors in mind.

We should also be clear about what research funding means in practice. It does not mean a guarantee of easy answers. Science does not work like that, but it does mean giving our best minds the chance to ask the right questions. It means building the evidence base and moving beyond a generic understanding of breast cancer and towards a more precise understanding of this specific disease. That is the direction of travel that we have seen over a number of years in modern healthcare. We have seen it in genomics and targeted therapies and we see it in the increasing recognition that treatment must be shaped by the biology of the disease and the needs of the patient. There is no reason that lobular breast cancer should be left behind in that progress.

There has been movement—it is right to acknowledge that. The National Institute for Health and Care Research has issued a highlight notice encouraging applications for research into lobular breast cancer; the Government have published their own national cancer plan; and the Health Bill speaks of research duties and innovation. Those are by no means meaningless, but they are not yet enough. That is why today’s debate must focus on delivery, so I ask the Minister whether the Government will set out a timeline to fund the lobular breast cancer Moon Shot Project. If the answer is yes, campaigners deserve to know how and through what mechanism that will happen. If the answer is no, they deserve an honest explanation. Is it a financial barrier? Is it a scientific one? Is it procedural? Are the Government waiting for further proposals, reviews or assessments? The people who have campaigned with such dignity on this issue should not be left trying to decode in silence.

I also ask the Minister to address the issue of guidance. Lobular breast cancer is referred to only in limited form in existing national breast cancer guidance, and campaigners have called for the National Institute for Health and Care Excellence to review whether the guidance properly reflects the disease. That guidance, of course, shapes clinical practice and influences what clinicians look for, what tests are considered and how treatment is approached. If the evidence is not yet strong enough to support separate recommendations, that should strengthen the case for targeted research, not weaken it. We cannot use the absence of evidence as a reason not to gather it. That would be a circular argument. The patients affected by this disease deserve much better.

There is also a wider lesson here about women’s health. Too often women’s symptoms have been dismissed as vague, complex or difficult to categorise. Too often women have had to become their own advocates at the very moment when they are frightened, unwell and least able to fight. One duty of a good health system is to reduce the burden on the patient and prove that they are worth listening to. Susan Michaelis understood that deeply. As we heard earlier, on 24 June last year, while on oxygen and clearly in pain, she stood outside Downing Street as part of a silent vigil representing the 22 people diagnosed every day with lobular breast cancer in the United Kingdom. She delivered a letter asking for help. Two weeks later she died wearing her Lobular Moon Shot Project T-shirt. That is an image that should stay with all of us today, not because policies should be made on emotion alone—clearly they should not. Policy has to be evidence-based, financially responsible and clinically sound. But should policy not be stripped of a moral seriousness, either. Evidence tells us what may work. Compassion reminds us why we keep working. Responsibility requires us to bring those two factors together.

The last Government invested in cancer research, including support for the Institute of Cancer Research and the Royal Marsden biomedical research centre, along with wider work relevant to lobular breast cancer. In opposition we have continued to press the Government on the Moon Shot Project, including through the shadow health team and other colleagues. But this should not, as we have discussed, become a party political contest. Cancer does not observe party lines, and neither should our determination to improve the outcomes for patients.

The test for the Government is relatively simple. Can they turn sympathy into a plan? Can they gave campaigners a clear route forward? Can they match the scale of the problem with a response that is specific, funded and time-bound? What those affected by lobular breast cancer need is not another expression of admiration for their bravery and courage. They need progress: a system that sees their cancer sooner, treatments shaped by its biology, surveillance that reflects the risk of recurrence and spread, guidance that recognises the particular character of the disease and research funded at a level that gives discovery a fair chance.

Susan Michaelis gave the final chapter of her life to this cause. She did so not for herself, but for women she would never meet and families she would never know. That legacy is worthy of more than a mere tribute; it is worthy of action. I hope the Minister will leave this debate having listened carefully, but also prepared to act decisively. The Government should not only meet the campaigners, but set out the remaining barriers, publish a route to a decision and make clear whether they will fund the Moon Shot project. Dr Susan Michaelis spent her life making hidden risks visible; the task before us now is to ensure that lobular breast cancer is hidden no longer.